JP2023529839A5 - - Google Patents

Info

Publication number
JP2023529839A5
JP2023529839A5 JP2022574459A JP2022574459A JP2023529839A5 JP 2023529839 A5 JP2023529839 A5 JP 2023529839A5 JP 2022574459 A JP2022574459 A JP 2022574459A JP 2022574459 A JP2022574459 A JP 2022574459A JP 2023529839 A5 JP2023529839 A5 JP 2023529839A5
Authority
JP
Japan
Prior art keywords
seq
peptide
amino acid
acid sequence
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022574459A
Other languages
English (en)
Japanese (ja)
Other versions
JP7733020B2 (ja
JP2023529839A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035580 external-priority patent/WO2021247789A1/en
Publication of JP2023529839A publication Critical patent/JP2023529839A/ja
Publication of JP2023529839A5 publication Critical patent/JP2023529839A5/ja
Application granted granted Critical
Publication of JP7733020B2 publication Critical patent/JP7733020B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022574459A 2020-06-04 2021-06-03 免疫調節性化合物 Active JP7733020B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034554P 2020-06-04 2020-06-04
US63/034,554 2020-06-04
PCT/US2021/035580 WO2021247789A1 (en) 2020-06-04 2021-06-03 Immunomodulatory compounds

Publications (3)

Publication Number Publication Date
JP2023529839A JP2023529839A (ja) 2023-07-12
JP2023529839A5 true JP2023529839A5 (cg-RX-API-DMAC7.html) 2024-06-10
JP7733020B2 JP7733020B2 (ja) 2025-09-02

Family

ID=76695836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574459A Active JP7733020B2 (ja) 2020-06-04 2021-06-03 免疫調節性化合物

Country Status (6)

Country Link
US (1) US11338040B2 (cg-RX-API-DMAC7.html)
EP (1) EP4161952A1 (cg-RX-API-DMAC7.html)
JP (1) JP7733020B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021283353A1 (cg-RX-API-DMAC7.html)
CA (1) CA3185657A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021247789A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020279371A1 (en) 2019-05-22 2021-12-23 Leidos, Inc. LAG 3 binding peptides
AU2021316230A1 (en) 2020-07-31 2023-03-16 Leidos, Inc. LAG3 binding peptides
JP2023548662A (ja) * 2020-10-12 2023-11-20 レイドス, インコーポレイテッド 免疫調節性ペプチド
WO2025193573A1 (en) * 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
PL345241A1 (en) 1998-05-06 2001-12-03 Upjohn Co Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
JP2008500013A (ja) 2003-10-03 2008-01-10 ザ ブライハム アンド ウイメンズ ホスピタル,インコーポレイテッド Tim−3ポリペプチド
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
MX2012009632A (es) 2010-02-18 2012-09-28 Athenix Corp Genes delta-endotoxinicos axmi221z, axmi222z, axmi223z, axmi224z, axmi225z y metodos para su uso.
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012055015A1 (en) 2010-10-26 2012-05-03 Alberta Health Services Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
CN102085735B (zh) 2010-11-09 2013-03-27 浙江大东南包装股份有限公司 一种多功能bopp烟用包装膜及其制造方法
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
BR112015007184A2 (pt) 2012-10-02 2017-08-08 Bristol Myers Squibb Co combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104072615B (zh) 2014-01-26 2016-08-24 中国人民解放军军事医学科学院基础医学研究所 一种能阻断Tim-3信号通路的人Tim-3融合蛋白
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
PH12020550847A1 (en) 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
JP2017535527A (ja) * 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス, インコーポレイテッド 新規のα4β7ペプチド単量体及び二量体拮抗薬
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
EP3206703B1 (en) 2014-10-14 2021-05-19 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Peptide for treating pancreatic cancer
WO2017023753A1 (en) 2015-07-31 2017-02-09 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
BR112018000366A2 (pt) * 2015-08-07 2018-09-11 Pieris Pharmaceuticals Gmbh polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
US9957325B2 (en) 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides
CN105504018B (zh) 2016-01-13 2019-01-04 郑州大学 Lag-3亲和肽n13、制备方法及其应用
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
DK3512536T3 (da) 2016-09-15 2020-11-23 Leidos Inc Pd-1-peptidinhibitorer
EP3630807B1 (en) * 2017-05-25 2025-08-13 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
CN107383174B (zh) 2017-08-21 2019-01-18 生工生物工程(上海)股份有限公司 一种能与pd-1特异性结合的肿瘤抑制肽及其用途
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3

Similar Documents

Publication Publication Date Title
ES2839880T3 (es) Vacuna contra el VRS
KR100808313B1 (ko) 비형 간염 코어 항원 융합 단백질
CN104271594B (zh) 用于初免‑加强疫苗的水疱性口炎病毒
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
JP2016128513A5 (cg-RX-API-DMAC7.html)
JP2012501959A5 (cg-RX-API-DMAC7.html)
JP2012500001A5 (cg-RX-API-DMAC7.html)
EP1504037A2 (en) Ferritin fusion proteins for use in vaccines and other applications
JP2008529558A5 (cg-RX-API-DMAC7.html)
JP2003511071A5 (cg-RX-API-DMAC7.html)
WO2021132379A1 (ja) 変異型rsv fタンパク質及びその利用
JP2008530975A5 (cg-RX-API-DMAC7.html)
CN115335064B (zh) 修饰的红细胞及其用于递送药剂的用途
JP2020509737A5 (cg-RX-API-DMAC7.html)
EP3077410A1 (en) Proline-rich peptides protective against s. pneumoniae
AU2002247084B2 (en) Hepatitis B virus treatment
JP2023542297A5 (cg-RX-API-DMAC7.html)
JP2023522154A5 (cg-RX-API-DMAC7.html)
CN1449407A (zh) 生理学上可接受的强酸加成盐形式的在其n-末端含有一个谷氨酸或一个谷氨酰胺的药用分子
CN1316431A (zh) 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
EP3342866B1 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
CN109415410B (zh) 靶向树突细胞的肽、利用了该肽的肽融合体、及利用了该肽融合体的疫苗
JP2004533846A5 (cg-RX-API-DMAC7.html)
JP2025511086A5 (cg-RX-API-DMAC7.html)
KR20180080178A (ko) 세균성 백신 및 바이러스성 백신 방법